# Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

> **NCT03740217** · PHASE1 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 15 (actual)

## Conditions studied

- Phase 1

## Interventions

- **DRUG:** GKT137831

## Key facts

- **NCT ID:** NCT03740217
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2019-02-06
- **Final completion:** 2019-02-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740217, "Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03740217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*